Abstract:Leigh syndrome (LS) is a severe mitochondrial disease that results from mutations in the nuclear or mitochondrial DNA that impairs cellular respiration and ATP production. Mutations in more than 100 genes have been demonstrated to cause LS. The disease most commonly affects brain development and function, resulting in cognitive and motor impairment. The underlying pathogenesis is challenging to ascertain due to the diverse range of symptoms exhibited by affected individuals and the variability in prognosis. To understand the disease mechanisms of different LS‐causing mutations and to find a suitable treatment, several different model systems have been developed over the last 30 years. This review summarizes the established disease models of LS and their key findings. Smaller organisms such as yeast have been used to study the biochemical properties of causative mutations. Drosophila melanogaster, Danio rerio, and Caenorhabditis elegans have been used to dissect the pathophysiology of the neurological and motor symptoms of LS. Mammalian models, including the widely used Ndufs4 knockout mouse model of complex I deficiency, have been used to study the developmental, cognitive, and motor functions associated with the disease. Finally, cellular models of LS range from immortalized cell lines and trans‐mitochondrial cybrids to more recent model systems such as patient‐derived induced pluripotent stem cells (iPSCs). In particular, iPSCs now allow studying the effects of LS mutations in specialized human cells, including neurons, cardiomyocytes, and even three‐dimensional organoids. These latter models open the possibility of developing high‐throughput drug screens and personalized treatments based on defined disease characteristics captured in the context of a defined cell type. By analyzing all these different model systems, this review aims to provide an overview of past and present means to elucidate the complex pathology of LS. We conclude that each approach is valid for answering specific research questions regarding LS, and that their complementary use could be instrumental in finding treatment solutions for this severe and currently untreatable disease.

IARS2 mutations lead to Leigh syndrome with a combined oxidative phosphorylation deficiency

Compound heterozygous mutation of the IARS2 gene: a rare cause of Leigh Syndrome

Mutations of Human NARS2, Encoding the Mitochondrial Asparaginyl-Trna Synthetase, Cause Nonsyndromic Deafness and Leigh Syndrome

Mechanisms and Future Research Perspectives on Mitochondrial Diseases Associated with Isoleucyl-tRNA Synthetase Gene Mutations

Novel biallelic mutations in TMEM126B cause splicing defects and lead to Leigh syndrome with severe complex I deficiency

A Novel Mitochondrial M.14430a>g (MT-ND6, P.w82r) Variant Causes Complex I Deficiency and Mitochondrial Leigh Syndrome

FARS2 Deficiency in Drosophila Reveals the Developmental Delay and Seizure Manifested by Aberrant Mitochondrial Trna Metabolism.

Novel NARS2 variant causing leigh syndrome with normal lactate levels

Genetic heterogeneity in Leigh syndrome: Highlighting treatable and novel genetic causes

Novel biallelic mutations in TMEM126B cause splicing defects and lead to Leigh-like syndrome with severe complex I deficiency

Leigh Syndrome: A Study of 209 Patients at the Beijing Children's Hospital

[A Case of Leigh Syndrome Associated with Respiratory Chain Complex I Deficiency Due to Mitochondrial Gene 13513G>A Mutation].

Clinical and molecular survey in 124 Chinese patients with Leigh or Leigh-like syndrome

Two novel mutations on SURF1 gene identified in a Chinese patient with Leigh Syndrome

Exclusion of sulfide:quinone oxidoreductase from mitochondria causes Leigh-like disease in mice by impairing sulfide metabolism

Whole‐exome sequencing identified novel variants in three Chinese Leigh syndrome pedigrees

Genetic and Biochemical Findings in Chinese Children with Leigh Syndrome.

Novel NDUFA13 Mutations Associated with OXPHOS Deficiency and Leigh Syndrome: A Second Family Report

Hearing impairment-associated KARS mutations lead to defects in aminoacylation of both cytoplasmic and mitochondrial tRNA Lys

Disease models of Leigh syndrome: From yeast to organoids

Bi‐allelic pathogenic variants in NDUFC2 cause early‐onset Leigh syndrome and stalled biogenesis of complex I